SGNTUC-024 Tucatinib plus trastuzumab and oxaliplatin-based chemotherapy for HER2+ gastrointestinal cancers

Clinical Trial Grant

Duke Scholars

Principal Investigator John Strickler Medicine, Medical Oncology

Awarded By

Seattle Genetics, Inc

Start Date

June 15, 2020

End Date

June 14, 2025

Awarded By

Seattle Genetics, Inc

Start Date

June 15, 2020

End Date

June 14, 2025